Kornimate/medical-research-clean huggingface dataset:
combined effect of insulin and sodium hyaluronate injection guided by ultrasound in carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: carpal tunnel syndrome (cts) is the most common peripheral entrapment neuropathy with involving compression of the median nerve in the carpal tunnel. the technique of perineural injection therapy (pit) is now commonly used for peeling the nerve from surrounding soft tissue (called nerve hydrodissection), which may help to reduce neuro-inflammation, ischemic damage and allow impulse transmission. the objective of this study is to evaluate the efficacy of ultrasound guided insulin plus sodium hyaluronate injection in reducing symptoms caused by carpal tunnel syndrome.

in this randomized clinical trial, 90 patients with both a clinical and electromyographic diagnosis of mild to moderate carpal tunnel syndrome will be recruited from assiut university hospital (auh). after obtaining written informed consent, patients will be randomized into three groups. group a, patients will receive ultrasound-guided pit with 10 iu of crystalline insulin; group b, patients will receive ultrasound-guided pit with 20 mg of sodium hyaluronate; group c, patients will receive ultrasound-guided pit with 10 iu of crystalline insulin and 20 mg of sodium hyaluronate. the primary outcome will be the boston carpal tunnel syndrome questionnaire - symptom severity scale at baseline, 1 month and 3 months post injection. all participants, investigator, outcomes assessor will be blinded (triple blind)

Eligibility criteria:
inclusion criteria: * aged 18 to 65 * understanding written and spoken arabic consent * diagnostic of carpal tunnel syndrome: classic of probable based on the katz hand diagram and mild to moderate based on the electrodiagnosis studies exclusion criteria: * diseases known to cause carpal tunnel syndrome: diabetes mellitus, hypothyroidism, connective tissue disease, rheumatic disease and moderate or severe chronic renal impairment * secondary diagnosis based on the ultrasound: arthrosynovial cyst, flexor tenosynovitis, ganglion * constant symptoms in medial nerve area * thenar eminence atrophy * cervical radiculopathy * brachial plexopathy * thoracic outlet syndrome * polyneuropathy * pregnancy * cognitive disorder * anticoagulant therapy * carpal tunnel injection in the last 6 months * ancient ipsilateral wrist fracture * ancient ipsilateral wrist surgery
heterogeneity of critical illness: a cohort study

Conditions: Critically Ill; Organ Failure, Multiple

Summary: rationale: there is large heterogeneity in disease states of critically ill patients at icu admittance and there is also large heterogeneity in their disease severity during icu stay. still, some patients may show remarkable similarities in disease patterns. there is a lack of understanding of causal mechanisms that lead to divergent outcomes in critically ill patients, and at the same time different diseases may share common underlying, yet unidentified, causal pathways that could explain similarities between different diseases. objective: to explore the association between patient characteristics and the severity of organ failure in critically ill patients admitted to the icu study design: prospective cohort study study population: adult critically ill patients in the icu intervention (if applicable): not applicable main study parameters/endpoints: maximum severity of organ failure observed during icu stay measured by the maximum sofa score and quality of life at one year follow-up

nature and extent of the burden and risks associated with participation, benefit and group relatedness: \<all patients will undergo physical examination, including ultrasound evaluation upon icu admission according to standard practice care. the burden will be a blood sample (and urine sample) at admission. blood sample will be obtained by arterial line (or venous access) which is part of standard icu care. so there will be no additional puncture for this study. collection of variables during icu stay will all be either part of standard clinical care or include extra physical examination or ultrasound evaluation. for follow-up patients will be evaluated by phone at 6 months and at 12 months by home-visit. this is also already part of the investigator's evaluation of quality of care. except for blood sampling, all study related procedures have previously been approved by the institutional review board (irb). the patient will experience no individual benefit.

Eligibility criteria:
inclusion criteria: * adults definition: age ≥18 years. * emergency admission to the icu definition: patients who are acutely admitted to the icu due to acute or unexpected critical illness, either from the emergency department or the ward or transferred from an icu (or a ward) from another hospital. exclusion criteria: * planned admission * absence of an invasive arterial or venous line for blood sampling. * any continued cardiopulmonary resuscitation efforts upon admission which limit access to the patient for research activities. * main icu admission reason chronic (non-invasive) home ventilation * main icu admission reason normothermic treatment after cardiac arrest * main icu admission reason ischemic stroke, intracerebral bleeding, or isolated neurotrauma * main icu admission reason coronavirus disease 2019 (covid-19) * solid organ or hematopoietic stem cell transplant during current hospital admission * strict isolation due to any contagious disease * no informed consent
a study of dcc-2701 in participants with advanced solid tumors

Conditions: Locally Advanced Tumors; Metastatic Solid Tumors; Cancers With MET Genomic Alterations; Cancers With TRK Genomic Alterations

Summary: the main purpose of this study is to investigate the safety of the investigational drug dcc-2701 and whether it will work to help people who have advanced solid tumors or cancer that has spread to other parts of the body.

this is a first-in-human study of dcc-2701. the primary purpose of this study is to determine what dose of dcc-2701, can be given safely to patients with advanced solid tumors. the study will have two phases. the first phase will assess escalating doses of dcc-2701 in order to determine the maximally tolerated dose (mtd) and the optimal dosing regimen (odr) of dcc-2701. once the mtd and odr is established, a dose expansion phase will further evaluate the safety of dcc-2701, as well as the activity of dcc-2701 in select solid tumor types.

Eligibility criteria:
inclusion criteria: * advanced or metastatic solid tumor that has progressed or was not responsive to standard therapy * the cancer has no proven effective therapy * the cancer can be biopsied (depending on the tumor type and/or the dose of drug received, tumor biopsies may be required) * able to swallow tablets exclusion criteria: * have active central nervous system (cns) metastasis * have an active infection of any kind (fungal, viral, or bacterial) * are pregnant or breastfeeding
cologne esophageal response prediction study (cerp-study)

Conditions: Esophageal Cancer

Summary: rationale: the prognosis of patients with advanced esophageal cancer may be improved by preoperative chemoradiation. but only those patients have a benefit from this additional therapy, whose tumor shows a response after chemoradiation. molecular markers may help to identify before starting the therapy those patients who response. purpose: this is the first prospective, clinical trial to study the impact of ercc1 to predict histopathological response to neoadjuvant radiochemotherapy (rtx/ctx) in patients with cancer of the esophagus.


Eligibility criteria:
inclusion criteria: * informed consent * newly diagnosed adenocarcinoma or squamous cell carcinoma of the esophagus or cardia exclusion criteria: * missing informed consent * prior radiation or chemotherapy * second malignancy

Keywords: esophagus chemoradiation excision repair cross-complementing gene polymorphism response prediction
tactile breast imaging sensor for tumor malignancy characterization

Conditions: Breast Cancer

Summary: the aim of this study is to see how well a tactile imaging sensor will detect for breast masses compared to traditional mammography and/or ultrasound. this device may allow a simple, convenient method to screen for breast tumors. this data will be used to check the feasibility of using the device to detect breast tumors.

the tactile imaging sensor will estimate the relative size and elasticity of the mass(es). this device may allow a simple, convenient method to screen for breast tumors. this is not a treatment and it will not be used to diagnose abnormal masses. the investigators will also not look for any unknown masses. and only doctors will touch the patients. an engineering assistant will be in the room to operate the tactile imaging sensor. the breast scan that is done as part of this research protocol is not intended to detect any breast disease or abnormality. research breast scans are not examined by a clinical radiologist to look for abnormalities. research scan will be evaluated by the engineers developing the device to assess its usefulness. the breast scan for this research will only look at a portion of your breast as it relates to this research. the investigators, the tactile imaging sensor operators and other members of the research team are not qualified to interpret the scan for any diagnostic or therapeutic value. therefore, the tactile imaging scan being done for this research study will not be analyzed to detect any medical condition. patients will have done mammography or ultrasound by now. once the doctor decides to perform biopsy, the tactile imaging will be planned. the consent will be obtained before the biopsy. one of the investigators (dr. caroline or dr. reilly) will obtain the consent. before the biopsy, the doctor will identify the mass(es) using other modalities such as a ultrasound. the tactile imaging sensor operator will obtain the tactile images. then the biopsy will be performed. radiology doctor, resident, and radiology technologist are always present during the procedure. in addition a professional assistant from the engineering group will operate the tactile imaging sensor. that person will not have any physical contact with you. the procedure will be very similar to the ultrasound device. the images will be analyzed by the investigators.

Eligibility criteria:
inclusion criteria: * women who had mammogram and/or ultrasound birads (category iv or v) * women ages between 30 and 80. * women who have been scheduled for biopsy from the temple breast surgery clinic * women who have been scheduled for biopsy by dr. kathleen reilly. * women, who speak and understand english. exclusion criteria: * women who do not meet the criteria requiring biopsy. * women who have allergic reaction to silicone. * women who cannot speak or understand english. * women who are pregnant. * women, younger than 30 years old, and older than 80 years old.

Keywords: breast cancer
a new anticoagulation method using dalteparin in quotidian and nocturnal home hemodialysis patients

Conditions: Kidney Failure

Summary: this study evaluates the optimal dosage and safety of dalteparin when used as an anticoagulant for hemodialysis therapies.

routine anticoagulation is required during hemodialysis treatments. in north america, the anticoagulant of choice for hemodialysis therapies is unfractionated heparin (ufh), whereas in western europe, it is low molecular weight heparin (lmwh). dalteparin is more commonly used in canada and has been approved for use in the in-centre thrice-weekly hemodialysis population at a fixed dose of 5000 units. however, there have been no published studies to assess the use of dalteparin in home quotidian and/or nocturnal hemodialysis therapies. patients on frequent hemodialysis or nocturnal hemodialysis in the home will be converted to dalteparin from heparin for 4 weeks to evaluate the optimal dosage and to assess its safety in this population

Eligibility criteria:
inclusion criteria: * currently undergoing short-hour daily and nocturnal hemodialysis through the home dialysis program at london health sciences centre. exclusion criteria: * patients with increased bleeding risks * currently on full dose anticoagulants * active bleeding * diabetic retinopathy * active cancer receiving treatment within the past 6 months

Keywords: dalteparin dosage home hemodialysis
64cu-sar-bbn for identification of participants with recurrence of prostate cancer (sabre)

Conditions: Biochemical Recurrence of Malignant Neoplasm of Prostate

Summary: the aim of this study is to determine the safety and efficacy of 64cu-sar-bbn and determine the ability of 64cu-sar-bbn positron emission tomography (pet)/computed tomography (ct) to correctly detect the recurrence of prostate cancer in participants with psma-negative biochemical recurrence of prostate cancer following definitive therapy.


Eligibility criteria:
inclusion criteria: 1. at least 18 years of age. 2. signed informed consent. 3. life expectancy ≥ 12 weeks as determined by the investigator. 4. histologically confirmed adenocarcinoma of prostate per original diagnosis and completed subsequent definitive therapy. 5. suspected recurrence of prostate cancer (pc) based on rising prostate specific antigen (psa) after definitive therapy on the basis of: 1. post-radical prostatectomy: detectable or rising psa that is ≥ 0.2 ng/ml with a confirmatory psa ≥ 0.2 ng/ml (per american urological association recommendation) or 2. post-radiation therapy, cryotherapy, or brachytherapy: increase in psa level that is elevated by ≥ 2 ng/ml above the nadir (per american society for therapeutic radiology and oncology-phoenix consensus definition). 6. negative or equivocal findings for pc on (1) approved psma pet and (2) anatomical imaging (ct and/or magnetic resonance imaging) and (3) if available, any other conventional imaging performed as part of routine standard of care imaging workup within 60 days prior to day 0. 7. the eastern cooperative oncology performance status 0-2. 8. adequate recovery from acute toxic effects of any prior therapy. 9. estimated glomerular filtration rate of 30 ml/min or higher. 10. adequate liver function. 11. for participants who have partners of childbearing potential: partner and/or participant must use a method of birth control with adequate barrier protection. exclusion criteria: 1. participants who received other investigational agents within 28 days prior to day 0. 2. participants administered any high energy (\>300 kiloelectronvolts (kev)) gamma-emitting radioisotope within 5 physical half-lives prior to day 0. 3. ongoing treatment or treatment within 90 days of day 0 with any systemic therapy (e.g. androgen-deprivation therapy, antiandrogen, gonadotropin-releasing hormone, luteinizing hormone-releasing hormone agonist or antagonist) for pc. 4. participants who are known to require prohibited treatment (e.g., initiation of androgen-deprivation therapy due to rapidly rising psa) before the 64cu-sar-bbn pet/ct results can be verified via histopathology or follow-up imaging. 5. known or expected hypersensitivity to 64cu-sar-bbn or any of its components. 6. any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.
mitraclip® registry

Conditions: Mitral Regurgitation

Summary: percutaneous mitral valve repair with the mitraclip® system has emerged as a therapeutic alternative to surgical valve repair (pmvr) in high risk patients. the aim of this registry is to collect prospectively and systematically clinical research data from patients undergoing pmvr with the mitraclip® system. this registry is an open-end observational study to assess the characteristics and outcomes patients with severe mitral regurgitation undergoing pmvr.


Eligibility criteria:
inclusion criteria: * severe mitral regurgitation * percutaneous mitral valve repair (pmvr) with the mitraclip® system exclusion criteria: * \< 18 years * patients considered by the heart team to be unlikely to receive meaningful or durable clinical benefit from the procedure

Keywords: mitral regurgitation mitraclip system percutaneous mitral valve repair
bendamustine plus rituximab versus chop plus rituximab

Conditions: Non-Hodgkin Lymphomas; Follicular Lymphomas; Immunocytomas; Lymphocytic Lymphomas; Marginal Zone Lymphomas

Summary: the study addresses the question if the first line therapy of low malignant and mantle cell lymphomas with bendamustine plus rituximab is comparable (non inferior) with chop plus rituximab with regard to progression free survival (pfs).

the 4 agent chemotherapy (ctx) chop (cyclophosphamide, doxorubicin, vincristine prednisone) in combination with the monoclonal anti-cd20 antibody rituximab (chop-r) represents a standard ctx for the treatment of lymphomas of high or low malignancy. the combination of bendamustine and rituximab (b-r) is also highly effective with a more advantageous toxicity profile. if b-r could be shown to be non inferior to chop-r, this could improve the quality of life of the patient and possibly also the prognosis.

Eligibility criteria:
inclusion criteria: * patients with histological verified cd20-positive b-cell-lymphomas of the following entities: * follicular lymphoma grade 1 and 2 * immunocytoma and lymphoplasmocytic lymphoma * marginal zone lymphoma, nodal and generalised * mantle cell lymphoma * lymphocytic lymphoma (cll without leucaemic characteristics) * non-specified/classified lymphomas of low malignancy * no prior therapy with cytotoxics,interferon or monoclonal antibodies * need for therapy, except mantle cell lymphomas * stadium iii or iv * written informed consent * performance status who 0-2 * histology not older than 6 months exclusion criteria: * patients not establishing all above mentioned prerequisites * option of a primary, potential curative radiation therapy * pretreatment except a unique local delimited radiation (radiation fiel not expanding two adjacent lymph node regions * comorbidities excluding a study conform therapy: * heart attack during the last 6 months * severe, medicinal not adjustable hypertonia * severe functional defects of the heart (nyha iii or iv) * lung (who grade iii or iv), liver or kidney (creatinine \> 2 mg/dl, got + gpt or bilirubin 3 x uln, except caused by lymphoma.

Keywords: comparison bendamustine + rituximab chop + rituximab progression free survival overall survival toxicity safety
focusing on the menopausal transition to improve mid-life women's health

Conditions: Menopause; Menopause Hot Flashes; Menopause Related Conditions; Cardiovascular

Summary: what if midlife women, who are inherently at an increased risk for future cardiometabolic disease due to transitioning into menopause, had access to a suite of evidence-based health interventions? could these interventions reduce menopause-related inflammation, restore a healthier cardiometabolic profile, reverse epigenetic aging, and reduce bothersome menopausal symptoms? the ultimate goal of this work is to attenuate future disease and enhance women's quality of life, extend healthspan and increase productivity.


Eligibility criteria:
inclusion criteria: * aged 45-55 * in the late menopausal transition, defined as 60 days of amenorrhea but less than 365 days of amenorrhea18 * no current use of hormone therapy or hormonal contraception * presence of a uterus and at least one ovary in order to track menstrual patterns * have a smartphone and broadband access adequate to accept telehealth appointments exclusion criteria: * lack of broadband access (activity and survey data will be collected electronically whenever possible and some visits will be via telehealth) * lack of regular menstrual periods in mid-reproductive life (ages 25-38) when not on hormones or not pregnant. * pregnancy or actively trying to get pregnant * inability to adhere to study protocol schedule * untreated alcoholism * un- diagnosed abnormal uterine bleeding * personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (men 2) for participants with a bmi\> 30 kg/m2.
comparison of infraclavicular brachial plexus block and local anesthesia in arteriovenous fistula surgeries and their effects on tissue oxygen saturation

Conditions: Renal Disease, Chronic

Summary: in arteriovenous fistula surgery, the effect of infraclavicular brachial plexus block and local anesthesia on tissue oxygenation and the effect of primary patency of the av fistula is intended to research.

it is planned to include patients who are american society of anesthesiologists (asa) iii and between the ages of 18-80 who will undergo arteriovenous fistula surgery in the research population.in our study, patients who come to the operating room for arteriovenous fistula operation will be randomly divided into two groups.patients who undergo simple randomization with coin toss method will be assigned to one of two groups: group local infiltrative anesthesia (local) and group infraclavicular brachial plexus block with 0.25% bupivacaine (block). local infiltrative anesthesia will be applied with 15 ml 2% prilocaine for group local patients.for group block patients, 30 ml 0.25% bupivacaine will be applied with infraclavicular approach around brachial plexus with inplane technique.before the start of surgery, nirs probes will be placed on the thenar ,antecubital regions of both hands and arms .the preoperative observed values and data of every 5 minutes during the operation will be recorded .

Eligibility criteria:
inclusion criteria: * asa iii * 18-80 years old * arteriovenous fistula operation exclusion criteria: * disabled patients * mentally retarded * patients with coagulopathy * hemoglobinopathy * patients with infection in the infraclavicular area * local anesthetic history * peripheral neuropathy * peripheral arterial occlusion * failed peripheral nerve block

Keywords: arteriovenous fistula operation infraclavicular nerve block near-infrared spectroscopy (nirs) local anesthesia
effect of oral zinc sulfate on jaundice in neonates admitted to neonatal intensive care unit

Conditions: Serum Bilirubin

Summary: a randomized double-blind clinical trial will be performed in the neonatal intensive care unit of makassed general hospital in beirut, lebanon from december 2021 till august 2022. randomized opaque envelopes to allocate the treatment will be used. the study will include neonates aged between 26 and 42 gestational weeks, who require phototherapy in the neonatal intensive care unit. patients will be randomized into two groups.both groups will receive standard conventional phototherapy, but the intervention group will receive 10 mg per day oral zinc sulfate until discharge.


Eligibility criteria:
inclusion criteria: * infants (post-menstrual age ≥ 26 weeks) delivered by cesarean section or vaginal delivery. * diagnosed to have hyperbilirubinemia: hyperbilirubinemia is defined as: * for term and near-term neonates (neonates less than 35 weeks' gestation): serum total bilirubin (stb) level that would qualify for phototherapy requirement as described in american academy of pediatrics 2004's guidelines or absolute stb level l 15 mg/dl; * for preterm neonates (\ 1% of body weight exclusion criteria: * infants less than 26 weeks postmenstrual age * allergy to zinc sulfate * any reaction seen after administration of first dose of zinc sulfate. * any contraindication to oral medication * infants with a history of taking phenobarbital by their mother